ASCO GU 2016

Progression Uncommon during Treatment with RA-223

San Francisco—Radium-223 (Ra-223), an alpha emitter that selectively targets bone metastases, has been shown to improve survival in patients with castration-resistant prostate cancer and bone metastasis and is standard treatment for those patients. However, according to researchers, the imaging response during Ra-223 therapy is not well defined. Daniel Keizman,  MD, and colleagues recently conducted a study designed to describe the ... Read More »

Responses in African American Men Treated with Abiraterone Acetate

San Francisco—Previous studies have documented a disparity between African Americans and other racial groups in incidence and mortality in prostate cancer. Abiraterone acetate was shown to improve overall survival and was approved by the US FDA for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). However, according to Michael D. Stolten, MD, and colleagues, phase III trials of ... Read More »

Survival Benefit of Abiraterone Acetate with Longer ADT Duration

San Francisco—Results of a retrospective review of clinical data of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 1000 mg abiraterone acetate daily plus 5 mg prednisone twice daily were reported during a poster session at the Genitourinary Cancers Symposium. The poster was titled Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer after Chemotherapy: A Real Life Retrospective Analysis of ... Read More »

Renal Function Not Impaired with Androgen Deprivation Therapy

San Francisco—There are known adverse effects associated with androgen deprivation therapy (ADT) in patients with prostate cancer; however, according to researchers there are few data on whether ADT affects renal function. Koji Mitsuzuka, MD, PhD, and colleagues conducted a study designed to assess changes in renal function in response to ADT for 1 year. Results of the study were presented ... Read More »

Definitive versus Adjuvant Radiation Therapy in Men with High-Risk Prostate Cancer

San Francisco— During a poster session at the Genitourinary Cancers Symposium, researchers led by Vasu Tumati, MD, presented results of an institutional review board-approved retrospective cohort study designed to clarify the optimal therapy for men with high-risk prostate cancer. The poster was titled Outcomes in Patients with High-Risk Prostate Cancer Treated with Definitive versus Adjuvant Radiation Therapy. Among men with ... Read More »

Post Hoc Analysis of Treatment Patterns of COU-AA-302 Patients

San Francisco—Researchers recently conducted a post hoc analysis of data on the patients in the abiraterone acetate arm of the COU-AA-302 trial. Thomas W. Flaig, MD, and colleagues presented results of the analysis during a poster session at the Genitourinary Cancers Symposium in a poster titled Treatment Patterns after Abiraterone Acetate in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): ... Read More »

Ongoing Trial of Concurrent Treatment with Radium-223 and Abiraterone Acetate in Men with CRPC with Symptomatic Bone Metastases

San Francisco—In a poster session at the Genitourinary Cancers Symposium, Neal Shore, MD, described an ongoing open-label phase II study evaluating the combinatorial use of concurrent abiraterone acetate plus radium Ra-223 dichloride (Ra-223) in men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. The poster was titled Open-Label Phase II Study Evaluating the Efficacy of Concurrent Administration of Radium ... Read More »

Early PSA Response Rate as Marker of Overall Survival

San Francisco—Drugs that have been approved over the past few years have created a change in the therapeutic options available for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate has been approved for the treatment of chemotherapy-naïve mCRPC patients following failure of androgen deprivation therapy and for the treatment of men with mCRPC who progress on ... Read More »

TAK-385 Effective and Safe in Advanced Prostate Cancer Patients: Phase II Trial Second Interim Results

San Francisco—TAK-385 is an investigational, oral, non-peptide gonadotropin-releasing hormone (GnRH) antagonist that is highly selective for the human GnRH receptor (IC50 0.12 nM). Fred Saad, MD, FRCSC, reported second interim analysis results from a phase II trial of TAK-385 during a poster session at the Genitourinary Cancers Symposium. The poster was titled Second Interim Analysis (IA2) Results from a Phase ... Read More »

Abiraterone Acetate Plus Glucocorticoid Regimens May Prevent Adverse Events Related to Mineralocorticoid Excess

San Francisco—Data from a recent open-label, multicenter, phase II trial suggest that prednisone at 5 mg twice a day in combination with abiraterone acetate, and 0.5 mg of dexamethasone once a day are effective in preventing mineralocorticoid excess that may be associated with adverse events in patients with metastatic castration-resistant prostate cancer (mCRPC). That finding was among those reported during ... Read More »